Related Experiment Video
Updated: Jul 12, 2025
03:01
Author Spotlight: A Reproductive Hysteroscopy Approach for Complete Endometrial Polyp Removal and Enhanced Endometrial Receptivity
Published on: August 2, 2024
722
Medical abortion in the second trimester - an update
1Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet.
Current Opinion in Obstetrics & Gynecology
|October 24, 2023
Summary
Second-trimester medical abortion using mifepristone and misoprostol is safe and effective, offering advantages over surgical methods. Careful patient selection and supportive care are crucial for optimal outcomes in this diverse patient group.
Area of Science:
- Reproductive Health
- Obstetrics & Gynecology
Background:
- Second-trimester medical abortion presents an alternative to surgical procedures.
- Provider independence may enhance accessibility in certain healthcare settings.
Purpose of the Study:
- To review the safety and efficacy of medical abortion in the second trimester.
- To discuss optimal regimens, complications, and supportive care for women undergoing this procedure.
Main Methods:
- Review of existing literature on second-trimester medical abortion.
- Analysis of effective medication regimens, including mifepristone and misoprostol.
- Discussion of complication rates and risk factors, such as uterine rupture.
Main Results:
- Medical abortion is generally safe and effective, with complications being rare.
- The combination of mifepristone and misoprostol is the most effective regimen.
- Uterine rupture is a rare but serious complication, particularly in women with prior cesarean delivery.
Conclusions:
- Second-trimester medical abortion is a viable option, with provider independence as a potential advantage.
- Optimal prostaglandin dosing requires further research.
- Comprehensive care, including pain relief, respectful treatment, and post-abortion contraception, is essential.
Related Concept Videos
01:19Mitral Valve Prolapse III: Nursing Management
14
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
14
01:07Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
01:27Ovarian Cycle
1.3K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.3K